Lonnie Pyne
@lonniepyne.bsky.social
Nephrologist
Assistant Professor
McMaster University
Assistant Professor
McMaster University
Will hopefully know more about phosphate levels soon from the ongoing PHOSPHATE trial.
#NephJC
www.clinicaltrials.gov/study/NCT035...
#NephJC
www.clinicaltrials.gov/study/NCT035...
ClinicalTrials.gov
www.clinicaltrials.gov
September 3, 2025 at 1:45 AM
Will hopefully know more about phosphate levels soon from the ongoing PHOSPHATE trial.
#NephJC
www.clinicaltrials.gov/study/NCT035...
#NephJC
www.clinicaltrials.gov/study/NCT035...
Unfortunately no. We tried to look for that based on the ACHIEVE results but the outcomes were poorly reported by sex in most trials included in the meta-analysis.
#NephJC
#NephJC
September 3, 2025 at 1:41 AM
Unfortunately no. We tried to look for that based on the ACHIEVE results but the outcomes were poorly reported by sex in most trials included in the meta-analysis.
#NephJC
#NephJC
Not 100% sure (been awhile since I signed off on any enrolment forms for ACHIEVE), but I don't recall race/ethnicity being recorded.
#NephJC
#NephJC
September 3, 2025 at 1:37 AM
Not 100% sure (been awhile since I signed off on any enrolment forms for ACHIEVE), but I don't recall race/ethnicity being recorded.
#NephJC
#NephJC
You got it. Pragmatic choice.
Equivalent dose in ESRD to that used in CV studies.
Most common dose used in prior trials in ESRD.
#NephJC
Equivalent dose in ESRD to that used in CV studies.
Most common dose used in prior trials in ESRD.
#NephJC
September 3, 2025 at 1:31 AM
You got it. Pragmatic choice.
Equivalent dose in ESRD to that used in CV studies.
Most common dose used in prior trials in ESRD.
#NephJC
Equivalent dose in ESRD to that used in CV studies.
Most common dose used in prior trials in ESRD.
#NephJC
First and only? Can’t be such a stickler as to ignore the PIVOTAL trial.
PIVOTAL trial effect estimate on all-cause mortality HR 0.84 (95% CI 0.71 to 1)
I do think expecting anything to improve all-cause mortality in ESRD is probably unwise.
www.nejm.org/doi/full/10....
PIVOTAL trial effect estimate on all-cause mortality HR 0.84 (95% CI 0.71 to 1)
I do think expecting anything to improve all-cause mortality in ESRD is probably unwise.
www.nejm.org/doi/full/10....
Intravenous Iron in Patients Undergoing Maintenance Hemodialysis | NEJM
Intravenous iron is a standard treatment for patients undergoing hemodialysis, but comparative data regarding clinically effective regimens are limited. In a multicenter, open-label trial with blin...
www.nejm.org
April 2, 2025 at 10:28 PM
First and only? Can’t be such a stickler as to ignore the PIVOTAL trial.
PIVOTAL trial effect estimate on all-cause mortality HR 0.84 (95% CI 0.71 to 1)
I do think expecting anything to improve all-cause mortality in ESRD is probably unwise.
www.nejm.org/doi/full/10....
PIVOTAL trial effect estimate on all-cause mortality HR 0.84 (95% CI 0.71 to 1)
I do think expecting anything to improve all-cause mortality in ESRD is probably unwise.
www.nejm.org/doi/full/10....